We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App





World's First Inhalable COVID-19 Vaccine Approved in China

By HospiMedica International staff writers
Posted on 06 Sep 2022

CanSino Biologics Inc. More...

(Tianjin, China) has received approval from the National Medical Products Administration of China (NMPA) for Convidecia Air, its recombinant COVID-19 vaccine (Adenovirus Type 5 Vector) for inhalation to be used as a booster dose.

Utilizing the same adenovirus vector technological platform as the company's intramuscular version Convidecia, Convidecia Air provides a non-invasive option that uses a nebulizer to change liquid into an aerosol for inhalation through the mouth. Convidecia Air is needle-free and can effectively induce comprehensive immune protection in response to SARS-CoV-2 after just one breath. Studies have indicated that Convidecia Air can induce strong humoral, cellular and mucosal immunity to achieve triple protection and effectively contain the infection and spread of the virus.

Related Links:
CanSino Biologics Inc. 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Immobilization System
Cranial 4Pi Immobilization
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Credit: Adobe Stock

Smaller Surgical Margins May Help Protect Healthy Tissue in Young Sarcoma Patients

Non-rhabdomyosarcoma soft tissue sarcomas arise in tissues that normally develop into muscles, nerves, and tendons. Removing these tumors in children and young adults requires balancing cancer clearance... Read more

Medical Imaging

view channel
Image: Medical imaging supports the planning of modern radiation therapy, with federated AI approaches possibly opening up new prospects. (Image Credit: Magali Hauser, KIT)

Privacy-Preserving AI Tool Synthesizes CT for Radiation Therapy Planning

Radiation therapy planning depends on accurate medical imaging to calculate dose, visualize organs, and position patients during treatment. Hospitals need large imaging datasets to train robust artificial... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.